FDA Seeks More Info On J&J’s New Pain Drug

Law360, New York (October 4, 2010, 12:25 PM EDT) -- Johnson & Johnson revealed Monday that U.S. health regulators have asked for additional data on the latest formulation of the drug giant’s pain management treatment tapentadol before giving the green light to the product.

The company said it had received a complete response letter from the U.S. Food and Drug Administration for J&J's tapentadol extended-release tablets.

While the FDA has not requested any new clinical studies evaluating the product's efficacy or safety, the agency is requesting data regarding the conversion of the extended-release formulation used in...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.